|
Dec 06 |
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Dec 03 |
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET...
Discussion topics to include pathology and... |
|
Nov 14 |
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results...
Conference call and webcast today at 8:30 a.m.... |
|
Nov 06 |
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time...
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Oct 22 |
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androg...
Study to evaluate PDS01ADC + Xtandi®... |
|
Oct 02 |
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with ...
100% 36-month overall survival (OS) and... |
|
Sep 16 |
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024...
Median Overall Survival remains at 30 months;... |
|
Sep 09 |
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024...
Presentation of data will take place on... |
|
Sep 03 |
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference...
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 13 |
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results...
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 08 |
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting...
PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 07 |
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024...
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 05 |
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024...
PRINCETON, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 01 |
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer...
Company to initiate Phase 3 VERSATILE-003 trial in... |
|
Jul 31 |
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time...
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Jul 29 |
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Jun 12 |
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer...
Majority of patients continue to be followed for... |
|
May 15 |
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results...
Provided Positive, Updated Data from Phase 2... |
|
May 09 |
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-...
30 month median overall survival (OS); median OS... |
|
May 09 |
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences...
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE)... |
|
May 07 |
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024...
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE)... |
|
May 03 |
PDS Biotechnology Announces Details of Virtual KOL Event...
Virtual Webinar Updated VERSATILE-002 Phase 2... |
|
May 02 |
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer...
Reports Inducement Grant Under Nasdaq Listing Rule... |
|
Apr 23 |
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial...
Company to Host Key Opinion Leader Event on May... |
|
Mar 27 |
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results...
Unique mechanism of action of the combination of PDS01ADC... |
|
Mar 20 |
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results...
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 13 |
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune...
Preclinical research published inVaccines... |
|
Jan 22 |
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Off...
Board-certified oncologist and hematologist... |
|
Jan 16 |
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference...
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS... |